| 1.125 0.205 (22.28%) | 03-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.55 |
1-year : | 1.81 |
| Resists | First : | 1.33 |
Second : | 1.55 |
| Pivot price | 1.15  |
|||
| Supports | First : | 1.06 |
Second : | 0.89 |
| MAs | MA(5) : | 1.06 |
MA(20) : | 1.18 |
| MA(100) : | 1.37 |
MA(250) : | 1.33 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 21.9 |
D(3) : | 14.5 |
| RSI | RSI(14): 45.6 |
|||
| 52-week | High : | 2.45 | Low : | 0.73 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MIRA ] has closed above bottom band by 40.4%. Bollinger Bands are 29.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.15 - 1.16 | 1.16 - 1.17 |
| Low: | 0.92 - 0.93 | 0.93 - 0.94 |
| Close: | 1.11 - 1.13 | 1.13 - 1.14 |
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
Mon, 23 Mar 2026
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Mon, 23 Mar 2026
MIRA’s Mira-55 shows no CNS side effects in preclinical tests - Investing.com
Mon, 23 Mar 2026
MIRA Pharmaceuticals Highlights Encouraging Safety Data for Mira-55 - TipRanks
Mon, 23 Mar 2026
Mira Pharmaceuticals reports preclinical results for Mira-55 with no observed THC- or rimonabant-like CNS side effects - Investing.com
Mon, 23 Mar 2026
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies - ACCESS Newswire
Mon, 23 Mar 2026
MIRA Pharmaceuticals (MIRA) posts Mira-55 CNS and pain preclinical data - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 42 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 16.6 (%) |
| Held by Institutions | 5.9 (%) |
| Shares Short | 568 (K) |
| Shares Short P.Month | 345 (K) |
| EPS | -1.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -74.7 % |
| Return on Equity (ttm) | -123.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.71 |
| PEG Ratio | 0 |
| Price to Book value | 5.92 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|